Home

articles

June 10, 2012

Latest from Home

pm2409_hero854x480_automation

Cell and gene therapy manufacturing challenges to persist in 2025

shutterstock_424978426

Key drugs losing patent protection in 2025

pm2411_hero854x480_coverstory

Going above and beyond

With a focus on CGT manufacturing, BioForge will be operational by 2027.

Pittsburgh’s biotech leap

pm2409_hero854x480_coverstory

Pharma’s new age of longevity

Notable 2024 FDA decisions